Form 4: VolitionRx CCO Gael Forterre Vests 38,100 RSUs

VolitionRx's Chief Commercial Officer, Gael Forterre, vested 38,100 restricted stock units, part of a larger award tied to performance goals and a three-year time-based schedule.

Summary

• Gael Forterre, Chief Commercial Officer of VOLITIONRX LTD (VNRX), acquired 38,100 shares of common stock on January 22, 2026, through the vesting of restricted stock units (RSUs).
• The RSUs were part of an initial award of 127,000 units granted on March 17, 2025, under the Issuer's 2024 Stock Incentive Plan.
• The vesting of 38,100 RSUs was contingent upon the achievement of certain corporate performance goals by June 30, 2025, and December 31, 2025.
• The remaining 88,900 RSUs from the original award did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• The 38,100 vested RSUs are subject to a further three-year time-based vesting schedule, with three equal installments of 12,700 units vesting on March 17, 2026, 2027, and 2028.
• Following this transaction, Gael Forterre directly beneficially owns 191,882 shares of common stock.
• Indirect beneficial ownership includes 5,000 shares by spouse and 32,500 shares by Armorica Partners, LLC, where Mr. Forterre is the managing director and sole shareholder.

Sentiment

Score: 6

Explanation: The vesting of 38,100 RSUs is a positive indicator of achieved corporate performance goals. However, the cancellation of a larger portion (88,900 RSUs) from the initial award tempers the overall positive sentiment, suggesting mixed results on performance targets.

Positives

• The vesting of 38,100 restricted stock units indicates that certain corporate performance goals were met, reflecting positively on the company's operational achievements.
• The transaction increases the Chief Commercial Officer's direct beneficial ownership, potentially aligning management interests with shareholder value.

Negatives

• A significant portion of the initial RSU award, 88,900 units out of 127,000, did not vest and was cancelled, suggesting that other corporate performance goals were not fully achieved.

Risks

• The non-vesting of a substantial portion of the RSU award (88,900 units) indicates that some performance targets were not met, which could signal challenges in achieving all strategic objectives.

Future Outlook

The 38,100 vested restricted stock units are subject to a future time-based vesting schedule, with shares to be received in three equal installments of 12,700 units on March 17, 2026, 2027, and 2028.

Industry Context

This insider transaction reflects a standard equity compensation event for a Chief Commercial Officer in a publicly traded company, aligning executive incentives with company performance and long-term shareholder value. The partial vesting and partial cancellation of RSUs are common outcomes depending on the achievement of specific performance metrics within the biotechnology or diagnostic industry.

Comparison to Industry Standards

• The structure of the RSU award, combining corporate performance goals and time-based vesting, is a common practice in executive compensation across various industries, including biotechnology and diagnostics, to incentivize both short-term performance and long-term retention.
• The partial achievement of performance goals, leading to partial vesting and cancellation, is a typical outcome for performance-based awards, reflecting the inherent challenges and specific targets set within competitive sectors.

Related Party Transactions

• Indirect beneficial ownership includes 5,000 shares held by the reporting person's spouse.
• Indirect beneficial ownership includes 32,500 shares held by Armorica Partners, LLC, where the reporting person is the managing director and sole shareholder, though beneficial ownership is disclaimed except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: The vesting of RSUs for a key executive can be seen as a positive signal of management's alignment with company performance, although the partial non-vesting might raise questions about overall goal achievement.
• Employees: The RSU program demonstrates the company's use of performance-based incentives for its leadership.

Next Steps

• The reporting person is scheduled to receive 12,700 shares of common stock on March 17, 2026, upon the first time-based vesting installment.
• Further installments of 12,700 shares are scheduled to vest on March 17, 2027, and March 17, 2028.

Key Dates

Keywords

VOLITIONRX LTD, VNRX, Gael Forterre, Chief Commercial Officer, Restricted Stock Units, RSU Vesting, Insider Transaction, SEC Form 4, Beneficial Ownership, Equity Compensation, Performance Goals